ATE428405T1 - Anionische hydrogelmatrizes mit ph-abhängiger modifizerter wirkstofffreisetzung als arzneimittelträger - Google Patents

Anionische hydrogelmatrizes mit ph-abhängiger modifizerter wirkstofffreisetzung als arzneimittelträger

Info

Publication number
ATE428405T1
ATE428405T1 AT05718991T AT05718991T ATE428405T1 AT E428405 T1 ATE428405 T1 AT E428405T1 AT 05718991 T AT05718991 T AT 05718991T AT 05718991 T AT05718991 T AT 05718991T AT E428405 T1 ATE428405 T1 AT E428405T1
Authority
AT
Austria
Prior art keywords
drug carriers
modified active
hydrogel matrices
active release
anionic hydrogel
Prior art date
Application number
AT05718991T
Other languages
English (en)
Inventor
Gaetano Giammona
Delia Mandracchia
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE428405T1 publication Critical patent/ATE428405T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05718991T 2004-04-01 2005-02-16 Anionische hydrogelmatrizes mit ph-abhängiger modifizerter wirkstofffreisetzung als arzneimittelträger ATE428405T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000168A ITRM20040168A1 (it) 2004-04-01 2004-04-01 Composizione a rilascio modificato ph dipendente.
PCT/IT2005/000081 WO2005094792A1 (en) 2004-04-01 2005-02-16 Anionic hydrogel matrices with ph dependent modified release as drug carriers

Publications (1)

Publication Number Publication Date
ATE428405T1 true ATE428405T1 (de) 2009-05-15

Family

ID=34961555

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05718991T ATE428405T1 (de) 2004-04-01 2005-02-16 Anionische hydrogelmatrizes mit ph-abhängiger modifizerter wirkstofffreisetzung als arzneimittelträger

Country Status (20)

Country Link
US (1) US20070166383A1 (de)
EP (1) EP1729732B1 (de)
JP (1) JP2007530666A (de)
KR (1) KR20060133578A (de)
CN (1) CN1913875B (de)
AT (1) ATE428405T1 (de)
AU (1) AU2005228716B2 (de)
BR (1) BRPI0509475A (de)
CA (1) CA2551797A1 (de)
CY (1) CY1109209T1 (de)
DE (1) DE602005013935D1 (de)
DK (1) DK1729732T3 (de)
ES (1) ES2325626T3 (de)
HR (1) HRP20090329T1 (de)
IT (1) ITRM20040168A1 (de)
PL (1) PL1729732T3 (de)
PT (1) PT1729732E (de)
RS (1) RS51178B (de)
SI (1) SI1729732T1 (de)
WO (1) WO2005094792A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4746883B2 (ja) * 2005-01-28 2011-08-10 リンテック株式会社 ハイドロゲル基剤、パップ剤基剤、パップ剤及び水性ゲルシート
EP2379697A2 (de) 2008-12-31 2011-10-26 3M Innovative Properties Company Probenahmevorrichtungen und verfahren zur aufkonzentration von mikroorganismen
US8609330B2 (en) 2008-12-31 2013-12-17 3M Innovative Properties Company Live Bioload detection using microparticles
WO2011082309A1 (en) 2009-12-30 2011-07-07 3M Innovative Properties Company Live bioload detection using microparticles
WO2011082258A2 (en) 2009-12-30 2011-07-07 Regents Of The University Of Minnesota Bone cement and method
KR101228106B1 (ko) * 2010-01-21 2013-02-01 광주과학기술원 피부투과도, 세포유입 및 종양전달성이 증가된 나노운반체
WO2011090349A2 (ko) * 2010-01-21 2011-07-28 광주과학기술원 피부투과도, 세포유입 및 종양전달성이 증가된 나노운반체
CN103330702B (zh) * 2013-07-02 2016-03-02 江苏长泰药业有限公司 含有拟交感神经胺盐和诱导凝胶体系的医药组合物
CN108452291A (zh) * 2018-07-04 2018-08-28 西南大学 用天然丝胶蛋白治疗溃疡性结肠炎的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4071508A (en) * 1975-02-11 1978-01-31 Plastomedical Sciences, Inc. Anionic hydrogels based on hydroxyalkyl acrylates and methacrylates
IT1284661B1 (it) * 1996-06-06 1998-05-21 Sigma Tau Ind Farmaceuti Uso di alcanoil l-carnitine nel trattamento terapeutico di malattie infiammatorie croniche intestinali.
DE19653631A1 (de) * 1996-12-20 1998-06-25 Basf Coatings Ag Verfahren zum Herstellen von durch Strahlung vernetzbaren polymeren Acryl- oder Methacrylsäureestern
AU736784B2 (en) * 1997-06-03 2001-08-02 Celltran Limited New medicaments based on polymers composed of methacrylamide-modified gelatin
CA2361555A1 (en) * 1999-02-03 2000-08-10 Powderject Research Limited Hydrogel particle formulations
US6547182B2 (en) * 2001-07-19 2003-04-15 Aerojet-General Corporation Solid rocket motor bolted thrust takeout structure
US7204997B2 (en) * 2002-01-29 2007-04-17 Supratek Pharma Inc. Responsive microgel and methods related thereto

Also Published As

Publication number Publication date
CN1913875B (zh) 2011-08-31
ITRM20040168A1 (it) 2004-07-01
RS51178B (sr) 2010-10-31
WO2005094792A1 (en) 2005-10-13
PT1729732E (pt) 2009-07-02
JP2007530666A (ja) 2007-11-01
BRPI0509475A (pt) 2007-09-11
AU2005228716A1 (en) 2005-10-13
US20070166383A1 (en) 2007-07-19
DE602005013935D1 (de) 2009-05-28
HRP20090329T1 (en) 2009-09-30
CA2551797A1 (en) 2005-10-13
EP1729732B1 (de) 2009-04-15
AU2005228716B2 (en) 2010-07-15
CY1109209T1 (el) 2014-07-02
PL1729732T3 (pl) 2009-09-30
SI1729732T1 (sl) 2009-08-31
DK1729732T3 (da) 2009-08-10
ES2325626T3 (es) 2009-09-10
EP1729732A1 (de) 2006-12-13
CN1913875A (zh) 2007-02-14
KR20060133578A (ko) 2006-12-26

Similar Documents

Publication Publication Date Title
ATE428405T1 (de) Anionische hydrogelmatrizes mit ph-abhängiger modifizerter wirkstofffreisetzung als arzneimittelträger
DOP2006000179A (es) 7-aza-indazoles sustituidos, composiciones que les contienen, procedimiento de fabricación y utilización
MXPA05007328A (es) Composiciones que contienen agentes antiacne y el uso de las mismas.
UA100851C2 (ru) Средство для борьбы с паразитами на животных
MXPA06014470A (es) Formulaciones oftalmicas que incluyen antagonistas de alfa 1 selectivas.
BRPI0518869A2 (pt) agentes citotàxicos compreendendo taxanos
TW200800967A (en) Benzimidazole thiophene compounds
EP2308870A3 (de) 2-Oxo-1-pyrrolidin-Derivate, Verfahren zu deren Herstellung und deren Verwendungen
TW200613500A (en) Michael addition compositions
TR201911270T4 (tr) Polimerik mirsen bileşimleri.
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
WO2008066630A3 (en) Methods for reprogramming adult somatic cells and uses thereof
MY145555A (en) Active compound-containing solid moulded bodies for external use against parasites on animals
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
GT200600121A (es) Novedosos derivados de triazolopirimidina
UA100850C2 (ru) Средство для борьбы с паразитами на животных
UY28812A1 (es) Agente parasiticida
WO2007025994A3 (fr) Utilisation d'au moins un 2-alkyle furane, a titre de principe actif depigmentant ou eclaircissant
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
UY28809A1 (es) Composiciones diuréticas de liberación prolongada
BRPI0510407A (pt) derivados de 3-amino-2-fenilpirrolidina
TNSN07438A1 (en) Prolonged release formulation of active principles having a ph-dependent solubility
TW200610526A (en) Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
ES2421520T3 (es) Potenciador de la producción de adiponectina
RU2006107412A (ru) 2,4,6-трифенил-4н-селенопиран-средство для лечения и профилактики отравлений соединениями мышьяка

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1729732

Country of ref document: EP